Menu
Search
|

Menu

Close
X

AnaptysBio Inc ANAB.OQ (NASDAQ Stock Exchange Global Select Market)

121.40 USD
+0.37 (+0.31%)
As of 8:41 PM IST
chart
Previous Close 121.03
Open 121.06
Volume 11,446
3m Avg Volume 142,696
Today’s High 122.03
Today’s Low 121.06
52 Week High 134.00
52 Week Low 18.18
Shares Outstanding (mil) 20.34
Market Capitalization (mil) 725.82
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
7
FY16
17
FY15
18
EPS (USD)
FY17
-0.880
FY16
-0.148
FY15
-0.282
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
55.97
5.77
Price to Book (MRQ)
vs sector
6.63
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
12.93
16.52
LT Debt to Equity (MRQ)
vs sector
10.06
12.22
Return on Investment (TTM)
vs sector
-23.31
14.43
Return on Equity (TTM)
vs sector
-48.33
16.13

EXECUTIVE LEADERSHIP

Hamza Suria
President, Chief Executive Officer, Director, Since 2011
Salary: $425,000.00
Bonus: --
Dominic Piscitelli
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Marco Londei
Chief Medical Officer, Since 2016
Salary: $380,000.00
Bonus: --
Hollings Renton
Lead Independent Director, Since 2015
Salary: --
Bonus: --
Carol Gallagher
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10421 Pacific Center Ct Ste 200
SAN DIEGO   CA   92121-4339

Phone: +1858.3626295

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

SPONSORED STORIES